TechTarget

techtarget.com

TechTarget (Nasdaq: TTGT) is the global leader in purchase intent-driven marketing and sales services that deliver business impact for enterprise technology companies. By creating abundant, high-quality editorial content across more than 140 highly targeted technology-specific websites, TechTarget attracts and nurtures communities of technology buyers researching their companies’ information technology needs. By understanding these buyers’ content consumption behaviors, TechTarget creates the purchase intent insights that fuel efficient and effective marketing and sales activities for clients around the world.

C-Suite On Deck

Responsive image

Q&A with John A. Steinert, Chief Marketing Officer at TechTarget

MEDIA 7 | October 17, 2019

John A. Steinert, Chief Marketing Officer at TechTarget helps bring the power of purchase intent-driven marketing and sales services to technology companies. With a strong drive to help customers achieve their business objectives faster and bigger, John and his TechTarget team connects the information needs of enterprise tech buyers and the go-to-market efforts of solution providers, ensuring that everybody wins. MEDIA 7: What inspired you to get into marketing? JOHN STEINERT: That’s easy. Marketing inspired me to get into marketing. I’ve always loved great communicators and the formats used in communications. As a kid during some pretty tumultuous times in American history, I was surrounded by great political, guerilla, and yes even commercial communications. Speeches, hearings, demonstrations, TV, advertisements, even album covers and t-shirts made a strong impression on me. Obviously, with the rise of the internet, long-tail video channels and social media, things have blossomed to an even more amazing level. M7: How does TechTarget's Priority Engine™ support tech vendors to achieve their marketing and sales objectives? JS: By helping companies see and interpret real buyer needs and preferences, Priority Engine first provides a relevant, permissioned basis for a marketer to intercept a buyer’s journey and then it assists users in taking very specific influencing and engagement actions. Because Priority Engine provides the actual permissioned people doing buying research, it saves tons of resource that’s commonly wasted chasing prospects who don’t have a need and leads that are actually dead ends. And because Priority Engine shares the real needs and preferences of the actual buyers with both marketing and sales when they share the platform, it enables far better conversion at every step, from funnel, to pipeline, through to renewal.

Read More

Events

Related News

PHARMACY MARKET, PHARMA TECH

SIMULATIONS PLUS ACQUIRES IMMUNETRICS TO EXPAND ITS IMMUNOLOGY AND ONCOLOGY DRUG DEVELOPMENT CAPABILITIES

Businesswire | June 21, 2023

news image

Simulations Plus, Inc. a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the acquisition of Immunetrics, Inc. (“Immunetrics”), a modeling and simulation company focused on accelerating drug development in oncology, immunology, and autoimmune diseases, areas that are among the fastest growing therapeutics. Under the terms of the Agreement, Simulations Plus agreed to pay the shareholders of Immun...

Read More

Pharmacy Market

VIRIDIAN THERAPEUTICS ANNOUNCES PARTNERSHIP WITH DRUG DELIVERY INNOVATOR ENABLE INJECTIONS

Globenewswire | May 15, 2023

news image

Viridian Therapeutics, Inc. a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, announced a new partnership with Enable Injections, a company developing and manufacturing the enFuse® innovative wearable drug delivery system for volumes of up to 25mL. “As we expand our pipeline beyond TED and assess the unmet needs of patients living with other serious and rare diseases, it’s clear that con...

Read More

Business Insights

AQEMIA ANNOUNCES PILOT STUDY WITH JANSSEN TO UTILIZE AQEMIA’S PHYSICS-DRIVEN DRUG DISCOVERY TECHNOLOGY

Aqemia | February 15, 2022

news image

Aqemia, the next-gen pharmatech company leveraging artificial intelligence and quantum-inspired physics announces it has entered into a pilot study agreement with Janssen. Through the agreement Aqemia’s unique technology to predict the potency of small molecules for a given target based on physics-based calculations will be applied to selected Janssen datasets. The agreement aims at building a common understanding of the performance of Aqemia’s technolog...

Read More

ALZECURE PHARMA PROVIDES A SCIENTIFIC UPDATE ON ALZHEIMER'S DISEASE AND THE ALZSTATIN PROJECT PLATFORM

AlzeCure Pharma | September 28, 2020

news image

CEO Martin Jönsson and CSO Johan Sandin will, among other things, present the pharmaceutical platform Alzstatin and the research behind it. Within the Alzstatin platform, AlzeCure develops disease-modifying and preventive drugs for Alzheimer's disease that focus on reducing the production of toxic amyloid beta (Aβ) in the brain. Henrik Zetterberg, chief physician and professor at the Department of Neuroscience and Physiology at Sahlgrenska Academy and professor at University Colleg...

Read More
news image

PHARMACY MARKET, PHARMA TECH

SIMULATIONS PLUS ACQUIRES IMMUNETRICS TO EXPAND ITS IMMUNOLOGY AND ONCOLOGY DRUG DEVELOPMENT CAPABILITIES

Businesswire | June 21, 2023

Simulations Plus, Inc. a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the acquisition of Immunetrics, Inc. (“Immunetrics”), a modeling and simulation company focused on accelerating drug development in oncology, immunology, and autoimmune diseases, areas that are among the fastest growing therapeutics. Under the terms of the Agreement, Simulations Plus agreed to pay the shareholders of Immun...

Read More
news image

Pharmacy Market

VIRIDIAN THERAPEUTICS ANNOUNCES PARTNERSHIP WITH DRUG DELIVERY INNOVATOR ENABLE INJECTIONS

Globenewswire | May 15, 2023

Viridian Therapeutics, Inc. a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, announced a new partnership with Enable Injections, a company developing and manufacturing the enFuse® innovative wearable drug delivery system for volumes of up to 25mL. “As we expand our pipeline beyond TED and assess the unmet needs of patients living with other serious and rare diseases, it’s clear that con...

Read More
news image

Business Insights

AQEMIA ANNOUNCES PILOT STUDY WITH JANSSEN TO UTILIZE AQEMIA’S PHYSICS-DRIVEN DRUG DISCOVERY TECHNOLOGY

Aqemia | February 15, 2022

Aqemia, the next-gen pharmatech company leveraging artificial intelligence and quantum-inspired physics announces it has entered into a pilot study agreement with Janssen. Through the agreement Aqemia’s unique technology to predict the potency of small molecules for a given target based on physics-based calculations will be applied to selected Janssen datasets. The agreement aims at building a common understanding of the performance of Aqemia’s technolog...

Read More
news image

ALZECURE PHARMA PROVIDES A SCIENTIFIC UPDATE ON ALZHEIMER'S DISEASE AND THE ALZSTATIN PROJECT PLATFORM

AlzeCure Pharma | September 28, 2020

CEO Martin Jönsson and CSO Johan Sandin will, among other things, present the pharmaceutical platform Alzstatin and the research behind it. Within the Alzstatin platform, AlzeCure develops disease-modifying and preventive drugs for Alzheimer's disease that focus on reducing the production of toxic amyloid beta (Aβ) in the brain. Henrik Zetterberg, chief physician and professor at the Department of Neuroscience and Physiology at Sahlgrenska Academy and professor at University Colleg...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Q&A with John A. Steinert, Chief Marketing Officer at TechTarget

MEDIA 7 | October 17, 2019

John A. Steinert, Chief Marketing Officer at TechTarget helps bring the power of purchase intent-driven marketing and sales services to technology companies. With a strong drive to help customers achieve their business objectives faster and bigger, John and his TechTarget team connects the information needs of enterprise tech buyers and the go-to-market efforts of solution providers, ensuring that everybody wins. MEDIA 7: What inspired you to get into marketing? JOHN STEINERT: That’s easy. Marketing inspired me to get into marketing. I’ve always loved great communicators and the formats used in communications. As a kid during some pretty tumultuous times in American history, I was surrounded by great political, guerilla, and yes even commercial communications. Speeches, hearings, demonstrations, TV, advertisements, even album covers and t-shirts made a strong impression on me. Obviously, with the rise of the internet, long-tail video channels and social media, things have blossomed to an even more amazing level. M7: How does TechTarget's Priority Engine™ support tech vendors to achieve their marketing and sales objectives? JS: By helping companies see and interpret real buyer needs and preferences, Priority Engine first provides a relevant, permissioned basis for a marketer to intercept a buyer’s journey and then it assists users in taking very specific influencing and engagement actions. Because Priority Engine provides the actual permissioned people doing buying research, it saves tons of resource that’s commonly wasted chasing prospects who don’t have a need and leads that are actually dead ends. And because Priority Engine shares the real needs and preferences of the actual buyers with both marketing and sales when they share the platform, it enables far better conversion at every step, from funnel, to pipeline, through to renewal.

Read More